خانه › سرطان کولورکتال › پنسیلوانیا › Pittsburgh
آزمایش‌های بالینی سرطان کولورکتال در Pittsburgh، PA
32 مطالعه برای سرطان کولورکتال در مراکز Pittsburgh (در شعاع حدود ۳۰ مایل) در جستجوی شرکت‌کننده هستند. یک مطالعه را باز کنید تا شرایط شرکت و نحوه تماس با تیم پژوهشی را ببینید.
متن رسمی مطالعه (انگلیسی)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
در حال جذب شرکت‌کنندهمرحله 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
در حال جذب شرکت‌کنندهمرحله 2
- Allegheny General Hospital, Pittsburgh
- West Penn Hospital, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Exelixis Clinical Site #32, Pittsburgh
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
در حال جذب شرکت‌کنندهمرحله 1
- Research Site, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
در حال جذب شرکت‌کنندهمرحله 1
- UPMC Hillman Cancer Center, Pittsburgh
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
در حال جذب شرکت‌کنندهمرحله 1/2
- University of Pittsburgh Medical Center (UPMC), Pittsburgh
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
در حال جذب شرکت‌کنندهمرحله 3
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center, Pittsburgh
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Research Site, Pittsburgh
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
در حال جذب شرکت‌کنندهمرحله 3
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center, Pittsburgh
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
در حال جذب شرکت‌کنندهمرحله 3
- Allegheny General Hospital, Pittsburgh
- West Penn Hospital, Pittsburgh
- Jefferson Hospital, Jefferson Hills · 11 مایل فاصله
- و 2 مورد دیگر
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
در حال جذب شرکت‌کنندهمرحله 2/3
- Local Institution - 0604, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
در حال جذب شرکت‌کنندهمرحله 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- Allegheny Health Network, Pittsburgh
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
در حال جذب شرکت‌کنندهمرحله 3
- Allegheny General Hospital Cancer Institute, Pittsburgh
- Hillman Cancer Center, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- UPMC Hillman Cancer Center, Pittsburgh
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
در حال جذب شرکت‌کنندهمرحله 3
- Clinical Study Site, Pittsburgh
- Clinical Study Site, Pittsburgh
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
در حال جذب شرکت‌کنندهمرحله 2
- UPMC / University of Pittsburgh Medical Center, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
در حال جذب شرکت‌کنندهمرحله 2
- UPMC Hillman Cancer Center, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
در حال جذب شرکت‌کنندهمرحله 1
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
در حال جذب شرکت‌کنندهمرحله 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
در حال جذب شرکت‌کنندهمرحله 3
- UPMC Hillman Cancer Center - St Margarets, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC Hillman Cancer Center - Passavant (HOA), Pittsburgh
- و 6 مورد دیگر
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar
در حال جذب شرکت‌کننده
- Allegheny Health Network, Pittsburgh
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
در حال جذب شرکت‌کنندهمرحله 1
- University of Pittsburg Medical Center (UPCM), Pittsburgh
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
در حال جذب شرکت‌کنندهمرحله 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
در حال جذب شرکت‌کننده
- AHN West Penn Hospital, Pittsburgh
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- UPMC Hillman Cancer Center, Pittsburgh
آزمایش‌های سرطان کولورکتال در سایر شهرها
- Houston, TX102 مطالعه
- New York City, NY78 مطالعه
- Nashville, TN69 مطالعه
- Boston, MA63 مطالعه
- Los Angeles, CA59 مطالعه
- Arlington, VA52 مطالعه
- St. Louis, MO50 مطالعه
- San Antonio, TX46 مطالعه
- Philadelphia, PA44 مطالعه
- Grand Rapids, MI40 مطالعه
- Baldwin Park, CA37 مطالعه
- Chicago, IL34 مطالعه
سایر مطالعات در Pittsburgh
- سرطان ریه غیرسلول کوچک48 مطالعه
- سرطان (همه انواع)41 مطالعه
- سرطان پستان39 مطالعه
- سرطان متاستاتیک31 مطالعه
- ملانوم31 مطالعه
- سرطان تخمدان30 مطالعه
- سرطان آندومتر23 مطالعه
- سرطان پروستات23 مطالعه
- سرطان ریه23 مطالعه
- کارسینوم سلول سنگفرشی سر و گردن22 مطالعه
- سکته مغزی22 مطالعه
- افسردگی22 مطالعه
از ClinicalTrials.gov، داده‌ها در تاریخ 6 اکتبر 2026 دریافت شده است. هر مطالعه شرایط اختصاصی خود را دارد؛ تیم پژوهشی تصمیم می‌گیرد چه کسانی می‌توانند شرکت کنند.